Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5063164 | 0.84 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CPDE3A | |
| SCHEMBL5483281 | 0.83 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2264024 | 0.83 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CAAK1 | |
| SCHEMBL2264284 | 0.82 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| SCHEMBL5509736 | 0.82 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CCYP2D6 | |
| SCHEMBL2267163 | 0.81 | PDE10A (0.44) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL5506883 | 0.81 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CCYP3A4 | |
| SCHEMBL5623979 | 0.79 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL5621856 | 0.79 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CPDE10A | |
| SCHEMBL5064560 | 0.79 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191413-A1 | Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | ATLANTA PHARMA AG (DE) | 2007-08-16 | — | — | US | claimed |
| EP-1812400-A1 | NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2007-08-01 | — | — | EP | claimed |
| WO-2005090311-A1 | NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-29 | — | — | WO | claimed |
| US-20070191413-A1 | Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | ATLANTA PHARMA AG (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1812400-A1 | NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2005090311-A1 | NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191413-A1 | Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.